uniQure N.V. (QURE)

4,4000 +0,0100 (+0,23%) In data: 11:32AM EDT. Mercato aperto.

uniQure N.V.

Paasheuvelweg 25
Amsterdam 1105 BP
Netherlands
31 20 240 6000
https://www.uniqure.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 480

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Matthew Craig Kapusta	CEO & Executive Director	1,02M	N/D	1972
Mr. Christian Klemt	CFO, Principal Financial Officer & GM of Amsterdam Site	575,46k	N/D	1973
Mr. Pierre Caloz	Chief Operating Officer	882,59k	N/D	1973
Mr. Richard Porter Ph.D.	Chief Business & Scientific Officer	732,17k	N/D	1968
Dr. Jeannette Potts J.D., Ph.D.	Chief Legal & Compliance Officer and Corporate Secretary	635,56k	N/D	1962
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/D	N/D	N/D
Dr. Tamara Tugal Ph.D., MBA	Business Development Director	N/D	N/D	N/D
Ms. Carla Poulson	Interim Chief People and Culture Officer	N/D	N/D	N/D
Ms. Maria E. Cantor	Chief Corporate Affairs Officer	491,12k	N/D	1968
Dr. Amin Abujoub Ph.D.	Chief Quality Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di uniQure N.V. al 29 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 1; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.